| FORM PTO 1449 (modified) | Atty. Docket No. X16616 | Serial No 10/597,165 | |
|---------------------------------------------------|----------------------------------------|-------------------------|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | First Applicant Jeffrey Alan Dodges | | |
| | Application Date | Group Art Unit | |
| | US Nat'l Entry (if applicable) | 1625 | |

| Exammer | Cite | Document Number | Publication Date | Name of Patentee or | Pages, Columns, Lines |
|-----------|-------|------------------------------------------|------------------|---------------------------------|-------------------------------------------------------|
| Initials* | No. 1 | Number-Kind Code ² (if known) | MM-DD-YYYY | Applicant of Cited Document | Where Relevant Pages or Relevant Figures Appear |
| /CC/ | AA | US 6 204 286 | 03-20-2001 | Cameron, Kimberly O., et al. | Claims 1-3, 16 |
| /CC/ | AB | US 5 510 357 | 04-23-1996 | Palkowitz, et al, | Claim 1 |

| ixaminer initials* | No.1 | Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-----------------------|------|--------------------------------------------------------------------------------------------------------------|--------------------------------|----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------|
| CC/ | BA | EP 0 791 591 | 08-27-1997 | Eli Lilly and Company | Claims 1,7; example 5 | |
| | BB | WO 01/54699 | 08-02-2001 | Endorecherche, Inc. | Claims 1, 14, 20 | |
| | BC | EP 1 199 069 | 04-24-2002 | Pfizer Products Inc. | Claim 7 | |
| | BD | EP 1 226 823 | 07-31-2002 | Pfizer Products Inc. | Claim 10 | |
| | BE | WO 02/03989 | 04-17-2002 | American Home Products Corp. | Claims 1, 5 | |
| | BF | WO 01/26651 | 04-19-2001 | Endorecherche, Inc. | Claims 1, 7, 13 | |
| | BG | WO 95/10513 | 04-20-1995 | Pfizer Inc.; Cameron, Kimberly O.; Da Silva-Jardine, Paul; Larson, Eric | Claims 1, 22 | |
| | ВН | WO 2004/009086 | 01-29-2004 | Eli Lilly and Company | Claims 1,7-9, 15-17 | |
| CC/ | BI | WO 2004/075894 | 09-10-2004 | Eli Lilly and Company | Claims 1, 4, 5 | |

| F . | | D . 0 . 1 . 1 | | |
|-----------|----------------|-----------------|------------|--|
| Examiner | /Celia Chang/ | Date Considered | 06/17/2009 | |
| Signature | /Gelia Griang/ | | 00/17/2009 | |
| | | | | |

^{*}EXAMINER: Install if reference consudered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's suape custom designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two letter code (WIPO Standard ST 3) *For Japanese patent documents, the industrion of the year of the reago of the Emperor must precede the serial number of the patent documents. *Stand of the Standard ST 3) *For Japanese patent documents.** Occurred by the appropure species, as mission for the demonstrator VERFO Standard TT Left possible. Supplies a species to spice a close that the first English Stangary Transitions is affected and the first English Stangary Transitions is affected and the spice of t

| FORM PTO 1449 (modified) | Atty. Docket No. X16616 | Serial No | |
|---------------------------------------------------|----------------------------------------------------|----------------|--|
| INFORMATION DISCLOSURE CITATION IN AN APPLICATION | First Applicant Jeffrey Alan Dodges | | |
| | Application Date US Nat'l Entry (if applicable) | Group Art Unit | |

| Examiner Initials* | No. 1 | Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published. | Т6 |
|-----------------------|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| /CC/ | CA | Miller, Chris P., et al., "Design, Synthesis and Preclinical Characterization of Novel, Highly Selective Indole Estrogens" <i>Journal of Medicinal Chemistry</i> , 44(11), 1654- 1657, 2001. | |
| | СВ | | |
| | СС | | |
| | CD | | |
| | CE | | |
| | CF | | |
| | CG | | |
| | СН | | |
| | CI | | |
| | CJ | | |
| | CK | | |
| | CL | | |
| | CM | | |
| | CN | | |
| | со | | |

| Examiner | | Date Considered | 06/17/2009 | |
|-----------|---------------|-----------------|------------|--|
| Signature | /Celia Chang/ | 7 | 00/11/2000 | |

^{*}EXAMINER: Install if reference consulered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹Applicant's suape custom designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two letter code (WIPO Standard ST 3) *For Japanese patent documents, the industrion of the year of the reago of the Emperor must precede the serial number of the patent documents. *Stand of the Standard ST 3) *For Japanese patent documents.** Occurred by the appropriant products an elected on the closures trade TMTO Standard T1 of Epochde **Opplement is to place a bother mark for all Taiglide Surgeous Transactions is standard to the Computer of the Computer of